NCT07598695 Sensory Feedback and Hand Motor Adaptation
| NCT ID | NCT07598695 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | The Catholic University of America |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2025-10-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The following experiment will be conducted with 15 chronic stroke survivors and 15 control subjects. Subjects will perform hand movements in the virtual reality environment using a head-mounted display. Quest's onboard cameras allow real-time tracking of hand motion, estimating joint angles of the finger and the thumb. For each feedback manipulation condition (i.e., movement amplification or reduction), the estimated joint angles will be multiplied by a factor greater than 1 (amplification) or a factor smaller than 1 (reduction). Then the newly-estimated hand posture will be displayed in the VR environment. Subjects will be randomly assigned into two groups (A and B), who will receive the assistance in a different order. Subjects will perform finger extension under three conditions: no sensory modulation, movement visual feedback (VF) amplification, and movement VF reduction (error augmentation), while their movement muscle activation patterns are recorded.
Eligibility Criteria
Inclusion Criteria for stroke group: * Age: 20 - 70 years old * First-ever unilateral cortical stroke with resultant hemiparesis at least 6 months prior to the experimental testing * Fugl-Meyer Upper Extremity Section 31 - 55 Exclusion Criteria for both groups: * Presence of concurrent severe medical illness * Pain in hand or arm with movements * Loss of voluntary control of fingers and thumb * Inability to provide informed consent * Musculoskeletal injuries (e.g., fracture) or medical complications (e.g., severe cardiovascular disease).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07598695 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 70 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07598695 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07598695 currently recruiting?
Yes, NCT07598695 is actively recruiting participants. Contact the research team at leesw@cua.edu for enrollment information.
Where is the NCT07598695 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT07598695 clinical trial?
NCT07598695 is sponsored by The Catholic University of America. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.